Everything below concerns ESI-MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid for research use |
| Solubility | Soluble in water and neutral buffers | Brief mixing may be needed |
| Storage temperature | -20 C or below | Desiccated, protected from light |
| Identity method | LC-MS or ESI-MS | Confirms molecular mass |
| Purity method | RP-HPLC with UV detection | Reported as percentage purity |
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
In the reaction 234U + n → 235U reaction, the 234U content of 4.5% enriched fuel drops steadily over the irradiation period falling from 450g/ton HM to 205g/ton HM in fuel with an irradiation of 60GWd/ton HM. Additionally, (n, 2n) reactions with fast neutrons also convert small amounts of 235U to 234U. This is countered by the rapid conversion of available 234U into 235U through thermal neutron capture. Uranium from spent nuclear fuel may contain as much as 0.010% 234U, or 100 parts per million, lower than the original fuel but still a higher fraction than natural uranium's 55 parts per million. Depleted uranium separated during the enrichment process contains much less 234U (around 0.001%), which reduces the alpha radioactivity almost half (the beta and gamma activity, which is from 234Th and 234Pa, is unchanged) compared to natural uranium having an equilibrium concentration of 234U in which an equal number of decays of 238U and 234U occur. Uranium-234, as well as uranium-232, is a byproduct, through further neutron capture, in reactors breeding thorium-232 into uranium-233.
Singapore imposed a ban on the opening of data centres in 2019 due to electric power, but lifted it in 2022. Although most nuclear plants in Japan have been shut down after the 2011 Fukushima nuclear accident, according to an October 2024 Bloomberg article in Japanese, cloud gaming services company Ubitus, in which Nvidia has a stake, is looking for land in Japan near a nuclear power plant for a new data centre for generative AI. On 1 November 2024, the Federal Energy Regulatory Commission (FERC) rejected an application submitted by Talen Energy for approval to supply some electricity from the nuclear power station Susquehanna to Amazon's data centre. According to the Commission Chairman Willie L. Phillips, it is a burden on the electricity grid as well as a significant cost-shifting concern to households and other business sectors. In 2025, a report prepared by the IEA estimated the greenhouse gas emissions from the energy consumption of AI at 180 million tons. By 2035, these emissions could rise to 300–500 million tonnes depending on what measures will be taken. This is below 1.5% of the energy sector emissions. The emissions reduction potential of AI was estimated at 5% of the energy sector emissions, but rebound effects (for example if people switch from public transport to autonomous cars) can reduce it. In June 2026, the United Nations University Institute for Water, Environment and Health released a report about cumulative environmental impacts of AI, not only carbon.
In early November 1938, under the First Vienna Award, which was a result of the Munich agreement, Czechoslovakia—which had failed to reach a compromise with Hungary and Poland—had to cede after the arbitration of Germany and Italy awarded southern Slovakia and Carpathian Ruthenia to Hungary, while Poland invaded Trans-Olza territory shortly after. As a result, Bohemia, Moravia and Silesia lost about 38% of their combined area to Germany, with some 3.2 million German and 750,000 Czech inhabitants. Hungary, in turn, received 11,882 km2 (4,588 sq mi) in southern Slovakia and southern Carpathian Ruthenia; according to a 1941 census, about 86.5% of the population in this territory was Hungarian. Meanwhile, Poland annexed the town of Český Těšín with the surrounding area (some 906 km2 (350 sq mi)), some 250,000 inhabitants, Poles making up about 36% of population, and two minor border areas in northern Slovakia, more precisely in the regions Spiš and Orava. (226 km2 (87 sq mi), 4,280 inhabitants, only 0.3% Poles). Soon after Munich, 115,000 Czechs and 30,000 Germans fled to the remaining rump of Czechoslovakia. According to the Institute for Refugee Assistance, the actual count of refugees on 1 March 1939 stood at almost 150,000. On 4 December 1938, there were elections in Reichsgau Sudetenland, in which 97.32% of the adult population voted for the National Socialist Party. About 500,000 Sudeten Germans joined the National Socialist Party, which was 17.34% of the German population in Sudetenland (the average National Socialist Party participation in Nazi Germany was 7.85%).
== Somatostatin receptor agonists versus antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time and unbound more slowly than the Lu-DOTA-TATE agonist.
In December 2022, the British government announced that it planned to open the Independent Inquiry relating to Afghanistan to investigate extrajudicial killings that took place between 2010 and 2013, during the War in Afghanistan. This followed a detailed BBC Panorama investigation that found members of the SAS "repeatedly killed detainees and unarmed men in suspicious circumstances". Panorama spoke to witnesses who alleged that operatives justified the killings of unarmed persons by leaving weapons at the scenes of the shootings and that SAS squadrons competed '"with each other to get the most kills". According to the investigation, officers of the UK Special Forces were concerned over the number of reports of detainees being killed after reaching for hidden weapons. Allegedly, several raids ended with the deaths of more people than weapons recovered. The BBC visited the sites of some raids and heard from ballistics experts who interpreted the bullet patterns present as more indicative "of execution-style killings rather than firefights". A formal internal review was opened at the time, but evidence was never passed to military police. The inquiry was launched in March 2023, to be chaired by Lord Justice Haddon-Cave. In September 2024, an internal Ministry of Defence document written in 2019 was presented to the inquiry that concluded that the BBC Panorama allegations were "broadly accurate".
Sources: en.wikipedia.org
== Discovery == GPX4 was first discovered in biochemistry laboratories of the University of Padua, where it was described as an enzyme capable of protecting against peroxidation. Its role as an inhibitor of cellular death was only discovered in 2012 by a research group Columbia University.
==== MeSH E05.318.308 – data collection ==== MeSH E05.318.308.225 – geriatric assessment MeSH E05.318.308.250 – health surveys MeSH E05.318.308.250.149 – behavioral risk factor surveillance system MeSH E05.318.308.250.300 – dental health surveys MeSH E05.318.308.250.300.300 – dental plaque index MeSH E05.318.308.250.300.350 – dmf index MeSH E05.318.308.250.300.675 – oral hygiene index MeSH E05.318.308.250.300.725 – periodontal index MeSH E05.318.308.250.475 – health status indicators MeSH E05.318.308.250.475.365 – apache MeSH E05.318.308.250.475.547 – severity of illness index MeSH E05.318.308.250.475.547.500 – karnofsky performance status MeSH E05.318.308.250.475.730 – sickness impact profile MeSH E05.318.308.250.580 – mass screening MeSH E05.318.308.250.580.174 – anonymous testing MeSH E05.318.308.250.580.350 – genetic screening MeSH E05.318.308.250.580.510 – mass chest x-ray MeSH E05.318.308.250.580.560 – multiphasic screening MeSH E05.318.308.250.580.580 – neonatal screening MeSH E05.318.308.250.580.925 – vision screening MeSH E05.318.308.250.600 – nutrition surveys MeSH E05.318.308.250.600.350 – diet surveys MeSH E05.318.308.250.700 – population surveillance MeSH E05.318.308.250.700.650 – sentinel surveillance MeSH E05.318.308.335 – health care surveys MeSH E05.318.308.420 – interviews MeSH E05.318.308.420.200 – focus groups MeSH E05.318.308.502 – narration MeSH E05.318.308.585 – nutrition assessment MeSH E05.318.308.585.550 – nutrition surveys MeSH E05.318.308.585.550.350 – diet surveys MeSH E05.318.308.750 – questionnaires MeSH E05.318.308.940 – records MeSH E05.318.308.940.250 – birth certificates MeSH E05.318.308.940.350 – death certificates MeSH E05.318.308.940.375 – dental records MeSH E05.318.308.940.425 – hospital records MeSH E05.318.308.940.968 – medical records MeSH E05.318.308.940.968.500 – medical record linkage MeSH E05.318.308.940.968.625 – medical records systems, computerized MeSH E05.318.308.940.968.750 – medical records, problem-oriented MeSH E05.318.308.940.968.875 – trauma severity indices MeSH E05.318.308.940.968.875.125 – abbreviated injury scale MeSH E05.318.308.940.968.875.250 – glasgow coma scale MeSH E05.318.308.940.968.875.260 – glasgow outcome scale MeSH E05.318.308.940.968.875.500 – injury severity score MeSH E05.318.308.940.984 – nursing records MeSH E05.318.308.970 – registries MeSH E05.318.308.970.725 – seer program MeSH E05.318.308.985 – vital statistics MeSH E05.318.308.985.450 – life expectancy MeSH E05.318.308.985.475 – life tables MeSH E05.318.308.985.525 – morbidity MeSH E05.318.308.985.525.080 – basic reproduction number MeSH E05.318.308.985.525.375 – incidence MeSH E05.318.308.985.525.750 – prevalence MeSH E05.318.308.985.550 – mortality MeSH E05.318.308.985.550.250 – cause of death MeSH E05.318.308.985.550.287 – child mortality MeSH E05.318.308.985.550.325 – fatal outcome MeSH E05.318.308.985.550.362 – fetal mortality MeSH E05.318.308.985.550.400 – hospital mortality MeSH E05.318.308.985.550.475 – infant mortality MeSH E05.318.308.985.550.500 – maternal mortality MeSH E05.318.308.985.550.900 – survival rate MeSH E05.318.308.985.775 – pregnancy rate MeSH E05.318.308.985.775.500 – birth rate
=== Intrinsic resistance === A few Gram-positive bacteria, such as Leuconostoc and Pediococcus, are intrinsically resistant to vancomycin, but they rarely cause disease in humans. Most Lactobacillus species are also intrinsically resistant to vancomycin, except for L. acidophilus and L. delbrueckii, which are sensitive. Other Gram-positive bacteria with intrinsic resistance to vancomycin include Erysipelothrix rhusiopathiae, Weissella confusa, and Clostridium innocuum. Most Gram-negative bacteria are intrinsically resistant to vancomycin because their outer membranes are impermeable to large glycopeptide molecules (with the exception of some non-gonococcal Neisseria species).
=== Opioid addiction === Methadone is used for the treatment of opioid use disorder. It may be used as maintenance therapy or in shorter periods to manage opioid withdrawal symptoms. Its use for the treatment of addiction is usually strictly regulated. In the US, outpatient treatment programs must be certified by the federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA) to prescribe methadone for opioid addiction. A 2009 Cochrane review found methadone was effective in retaining people in treatment and the reduction or cessation of heroin use as measured by self-report and urine/hair analysis and did not affect criminal activity or risk of death. Treatment of opioid-dependent persons with methadone follows one of two routes: maintenance or withdrawal management. Methadone maintenance therapy (MMT) usually takes place in outpatient settings. It is usually prescribed as a single daily dose medication for those who wish to abstain from illicit opioid use. Treatment models for MMT differ. It is not uncommon for treatment recipients to be administered methadone in a specialized clinic, where they are observed for around 15–20 minutes post-dosing, to reduce the risk of diversion of medication. The duration of methadone treatment programs ranges from a few months to years. Given opioid dependence is characteristically a chronic relapsing/remitting disorder, MMT may be lifelong. The length of time a person remains in treatment depends on a number of factors.
Sources: en.wikipedia.org
Structural effects can also be important. The difference between fumaric acid and maleic acid is a classic example. Fumaric acid is (E)-1,4-but-2-enedioic acid, a trans isomer, whereas maleic acid is the corresponding cis isomer, i.e. (Z)-1,4-but-2-enedioic acid (see cis-trans isomerism). Fumaric acid has pKa values of approximately 3.0 and 4.5. By contrast, maleic acid has pKa values of approximately 1.5 and 6.5. The reason for this large difference is that when one proton is removed from the cis isomer (maleic acid) a strong intramolecular hydrogen bond is formed with the nearby remaining carboxyl group. This favors the formation of the maleate H+, and it opposes the removal of the second proton from that species. In the trans isomer, the two carboxyl groups are always far apart, so hydrogen bonding is not observed.
Intra-articular steroid injections often help with treatment in oligoarticular JIA. Conventional synthetic DMARDs, such as methotrexate are a first-line therapy, and biologic DMARDs such as TNF-α inhibitors may be added on for refractory cases. Rheumatoid factor-negative polyarticular JIA (15-20% of all JIA cases) can be treated with synthetic conventional DMARDs (such as methotrexate), with biologic DMARDs (such as TNF inhibitors) being a second-line add-on treatment option. Rheumatoid factor-positive JIA (5% of JIA cases, and also being rare in children younger than 9-years old) is associated with a poor prognosis, and early treatment is required to prevent significant joint destruction and disability. It is very similar pathologically to adult rheumatoid arthritis. Synthetic conventional DMARDs or biologic DMARDs are standard therapy for this type of JIA. Enthesitis-related arthritis is a type of JIA characterized by enthesitis; inflammation of the area where tendons and ligaments attach to bone. NSAIDs are commonly used for symptomatic relief, with the anti-inflammatories sulfasalazine and TNF inhibitors also being used. Biologic DMARDs such as TNF-α inhibitors are used for sacroilitis (inflammation of the sacroiliac joint). IL-17 inhibitors are used for refractory disease. 40-60% of children with enthesitis-related variant of JIA have involvement of the axial skeleton, including sacroiliitis, spondyloarthritis, and ankylosing spondylitis (inflammation of the spine).
It is a colourless paramagnetic gas that, being thermodynamically unstable, decomposes to nitrogen and oxygen gas at 1100–1200 °C. Its bonding is similar to that in nitrogen, but one extra electron is added to a π* antibonding orbital and thus the bond order has been reduced to approximately 2.5; hence dimerisation to O=N–N=O is unfavourable except below the boiling point (where the cis isomer is more stable) because it does not actually increase the total bond order and because the unpaired electron is delocalised across the NO molecule, granting it stability. There is also evidence for the asymmetric red dimer O=N–O=N when nitric oxide is condensed with polar molecules. It reacts with oxygen to give brown nitrogen dioxide and with halogens to give nitrosyl halides. It also reacts with transition metal compounds to give nitrosyl complexes, most of which are deeply coloured. Blue dinitrogen trioxide (N2O3) is only available as a solid because it rapidly dissociates above its melting point to give nitric oxide, nitrogen dioxide (NO2), and dinitrogen tetroxide (N2O4). The latter two compounds are somewhat difficult to study individually because of the equilibrium between them, although sometimes dinitrogen tetroxide can react by heterolytic fission to nitrosonium and nitrate in a medium with high dielectric constant. Nitrogen dioxide is an acrid, corrosive brown gas. Both compounds may be easily prepared by decomposing a dry metal nitrate. Both react with water to form nitric acid.
Sources: en.wikipedia.org
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.
Each cycle can cause aggregation and adsorption losses that lower measured peptide content. Dividing a solution into single-use aliquots reduces this risk.
Reversed-phase chromatography reports purity, while mass spectrometry confirms identity through molecular mass. Amino acid analysis adds composition data.
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.